These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 18184079)

  • 1. Evolution of genotypic and phenotypic resistance during chronic treatment with the fusion inhibitor T-1249.
    Melby T; Demasi R; Cammack N; Miralles GD; Greenberg ML
    AIDS Res Hum Retroviruses; 2007 Nov; 23(11):1366-73. PubMed ID: 18184079
    [TBL] [Abstract][Full Text] [Related]  

  • 2. T-1249 retains potent antiretroviral activity in patients who had experienced virological failure while on an enfuvirtide-containing treatment regimen.
    Lalezari JP; Bellos NC; Sathasivam K; Richmond GJ; Cohen CJ; Myers RA; Henry DH; Raskino C; Melby T; Murchison H; Zhang Y; Spence R; Greenberg ML; Demasi RA; Miralles GD;
    J Infect Dis; 2005 Apr; 191(7):1155-63. PubMed ID: 15747252
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evolution of genotypic and phenotypic resistance to Enfuvirtide in HIV-infected patients experiencing prolonged virologic failure.
    Poveda E; Rodés B; Labernardière JL; Benito JM; Toro C; González-Lahoz J; Faudon JL; Clavel F; Schapiro J; Soriano V
    J Med Virol; 2004 Sep; 74(1):21-8. PubMed ID: 15258964
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of human immunodeficiency virus type 1 gp41 amino acid substitutions selected during enfuvirtide treatment on gp41 binding and antiviral potency of enfuvirtide in vitro.
    Mink M; Mosier SM; Janumpalli S; Davison D; Jin L; Melby T; Sista P; Erickson J; Lambert D; Stanfield-Oakley SA; Salgo M; Cammack N; Matthews T; Greenberg ML
    J Virol; 2005 Oct; 79(19):12447-54. PubMed ID: 16160172
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Resistance and replicative capacity of HIV-1 strains selected in vivo by long-term enfuvirtide treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    New Microbiol; 2004 Apr; 27(2 Suppl 1):51-61. PubMed ID: 15646065
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Drug profile: enfuvirtide (Fuzeon, ENF, T-20).
    Pham PA
    Hopkins HIV Rep; 2003 May; 15(3):1-2. PubMed ID: 12809104
    [No Abstract]   [Full Text] [Related]  

  • 7. Characterization of determinants of genotypic and phenotypic resistance to enfuvirtide in baseline and on-treatment HIV-1 isolates.
    Sista PR; Melby T; Davison D; Jin L; Mosier S; Mink M; Nelson EL; DeMasi R; Cammack N; Salgo MP; Matthews TJ; Greenberg ML
    AIDS; 2004 Sep; 18(13):1787-94. PubMed ID: 15316339
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Role of the envelope genetic context in the development of enfuvirtide resistance in human immunodeficiency virus type 1-infected patients.
    Labrosse B; Morand-Joubert L; Goubard A; Rochas S; Labernardière JL; Pacanowski J; Meynard JL; Hance AJ; Clavel F; Mammano F
    J Virol; 2006 Sep; 80(17):8807-19. PubMed ID: 16912327
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics of enfuvirtide resistance mutations in enfuvirtide-experienced patients remaining in virological failure under salvage therapy.
    Charpentier C; Jenabian MA; Piketty C; Karmochkine M; Tisserand P; Laureillard D; Bélec L; Si-Mohamed A; Weiss L
    Scand J Infect Dis; 2011 May; 43(5):373-9. PubMed ID: 21341978
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Genotypic changes in human immunodeficiency virus type 1 envelope glycoproteins on treatment with the fusion inhibitor enfuvirtide and their influence on changes in drug susceptibility in vitro.
    Su C; Melby T; DeMasi R; Ravindran P; Heilek-Snyder G
    J Clin Virol; 2006 Aug; 36(4):249-57. PubMed ID: 16765082
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Virological fitness of HIV in patients with resistance to enfuvirtide.
    Chibo D; Roth N; Roulet V; Skrabal K; Gooey M; Carolan L; Nicholls J; Papadakis A; Birch C
    AIDS; 2007 Sep; 21(14):1974-7. PubMed ID: 17721108
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genotype and phenotype patterns of human immunodeficiency virus type 1 resistance to enfuvirtide during long-term treatment.
    Menzo S; Castagna A; Monachetti A; Hasson H; Danise A; Carini E; Bagnarelli P; Lazzarin A; Clementi M
    Antimicrob Agents Chemother; 2004 Sep; 48(9):3253-9. PubMed ID: 15328081
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Long-term monitoring of genotypic and phenotypic resistance to T20 in treated patients infected with HIV-1.
    Pérez-Alvarez L; Carmona R; Ocampo A; Asorey A; Miralles C; Pérez de Castro S; Pinilla M; Contreras G; Taboada JA; Nájera R
    J Med Virol; 2006 Feb; 78(2):141-7. PubMed ID: 16372284
    [TBL] [Abstract][Full Text] [Related]  

  • 14. HIV resistance to the fusion inhibitor enfuvirtide: mechanisms and clinical implications.
    Miller MD; Hazuda DJ
    Drug Resist Updat; 2004 Apr; 7(2):89-95. PubMed ID: 15158765
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Emergence and evolution of enfuvirtide resistance following long-term therapy involves heptad repeat 2 mutations within gp41.
    Xu L; Pozniak A; Wildfire A; Stanfield-Oakley SA; Mosier SM; Ratcliffe D; Workman J; Joall A; Myers R; Smit E; Cane PA; Greenberg ML; Pillay D
    Antimicrob Agents Chemother; 2005 Mar; 49(3):1113-9. PubMed ID: 15728911
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enfuvirtide resistance mutations: impact on human immunodeficiency virus envelope function, entry inhibitor sensitivity, and virus neutralization.
    Reeves JD; Lee FH; Miamidian JL; Jabara CB; Juntilla MM; Doms RW
    J Virol; 2005 Apr; 79(8):4991-9. PubMed ID: 15795284
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Performance of human immunodeficiency virus type 1 gp41 assays for detecting enfuvirtide (T-20) resistance mutations.
    Marcial M; Lu J; Deeks SG; Ziermann R; Kuritzkes DR
    J Clin Microbiol; 2006 Sep; 44(9):3384-7. PubMed ID: 16954280
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Analysis of HIV type 1 gp41 and enfuvirtide susceptibility among men in the United States who were HIV infected prior to availability of HIV entry inhibitors.
    Hudelson SE; Marlowe N; Huang W; Bruce R; Church JD; Husnik M; Donnell D; Coates T; Jackson JB; Chesney M; Koblin B; Eshleman SH
    AIDS Res Hum Retroviruses; 2009 Jul; 25(7):701-5. PubMed ID: 19552592
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dynamics of enfuvirtide resistance in HIV-infected patients during and after long-term enfuvirtide salvage therapy.
    Poveda E; Rodés B; Lebel-Binay S; Faudon JL; Jimenez V; Soriano V
    J Clin Virol; 2005 Dec; 34(4):295-301. PubMed ID: 16286053
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genotypic analysis of the gp41 HR1 region from HIV-1 isolates from enfuvirtide-treated and untreated patients.
    Pessoa LS; Valadão AL; Abreu CM; Calazans AR; Martins AN; Azevedo SS; Couto-Fernandez JC; Azevedo MC; Tanuri A
    J Acquir Immune Defic Syndr; 2011 Aug; 57 Suppl 3():S197-201. PubMed ID: 21857318
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.